$NBIO "Having completed the first three cohorts, we are excited to move to our fourth and possibly final cohort in the Phase I trial. The third cohort took longer than expected but the data received is very useful moving forward," noted Nascent CEO, Sean Carrick, https://twitter.com/Nascent_BioTech/status/15...3154325504